Shares of pharma conglomerate Bayer BAYRY were down 7.1% on March 24, following a setback in the ongoing Roundup Litigation.Bayer reported that, on March 21, the jury at the Barnes Roundup trial in the...
Novo Nordisk NVO announced an update to the savings offer for its popular obesity injection, Wegovy (semaglutide). This update allows cash-paying patients or those with commercial insurance, which does...
The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due to the better-than-expected fourth-quarter performance of large drugmakers and...
Novo Nordisk will obtain exclusive worldwide rights to develop, manufacture, and commercialize the drug UBT251, while United Biotechnology will, however, retain the rights to the drug in mainland China,...
There's a price war brewing in GLP-1 weight loss drugs, and now it's going global.
Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time frame,...
It all comes down to this...the final round of the Motley Fool Rule Breaker Investing March Market Cap Showdown! Defending Champion Andy Cross has held off all contenders and pretenders, but game show...
President Donald Trump has been in office for only two months, but already his saber-rattling over tariffs has roiled markets.
Abbvie made an all-time high after announcing an agreement that puts it in the weight loss market; but that just continues a general uptrend in ABBV stock
It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug market is expected to generate $12.8 billion in sales this year, and according...
GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. The stock has...
Wondering if you should look beyond American markets to build your fortune? This widely held international fund offers a few opportunities and several challenges.
In this video, I will cover the recent updates regarding Novo Nordisk (NYSE: NVO) . Watch the short video to learn more, consider subscribing, and click the special offer link below.
Novo Nordisk (NYSE: NVO), the Danish company best known as the maker of weight loss drug Wegovy, expanded a little on the stock exchange Tuesday. The company was one of the rare enterprises seeing an increase...
Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry.AMGN Stock PerformanceImage Source: Zacks Investment ResearchAmgen’s stock has been rising consistently,...
Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.
Morgan Stanley had great news for Hims & Hers stock today, so why didn't it upgrade the stock?
Are you reluctant to invest in stocks right now? That's understandable. Fear, uncertainty, and doubt have become the norm in early 2025 with rising stock market volatility .
/AMGEN%20Inc_%20logo%20on%20meds-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Amgen is hoping to rival Novo Nordisk and Eli Lilly in the weight-loss drug market.
Here is what investors should expect from the upcoming conference.